Published in Cancer Discov on January 16, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet (2015) 2.46
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol (2015) 2.33
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol (2014) 2.28
Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 2.15
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol (2015) 2.00
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal (2013) 1.96
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol (2014) 1.76
Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol (2012) 1.72
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell (2015) 1.71
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov (2015) 1.70
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57
Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Mol Cell (2015) 1.47
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One (2015) 1.43
Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. Surgery (2015) 1.41
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One (2012) 1.30
The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol (2014) 1.22
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res (2013) 1.21
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther (2014) 1.18
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer (2015) 1.15
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A (2014) 1.15
Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov (2013) 1.10
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07
Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol (2017) 1.06
Targeting cancer with kinase inhibitors. J Clin Invest (2015) 1.05
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02
p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol (2014) 1.02
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep (2014) 1.01
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res (2016) 1.00
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nat Med (2015) 0.98
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov (2013) 0.98
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med (2013) 0.97
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol (2014) 0.96
BRAF Mutation in Colorectal Cancer: An Update. Biomark Cancer (2015) 0.95
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer (2015) 0.94
Important molecular genetic markers of colorectal cancer. Oncotarget (2016) 0.94
BRAF inhibitors in clinical oncology. F1000Prime Rep (2013) 0.93
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget (2015) 0.92
Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther (2014) 0.92
MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol (2015) 0.91
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene (2014) 0.91
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One (2012) 0.91
"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett (2014) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res (2014) 0.91
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J (2014) 0.90
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol (2014) 0.90
Biology of colorectal cancer. Ecancermedicalscience (2015) 0.90
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Adaptive resistance to targeted therapies in cancer. Transl Lung Cancer Res (2013) 0.89
Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nat Commun (2014) 0.88
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol (2014) 0.88
Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res (2012) 0.88
Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Mol Cancer Res (2015) 0.87
KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res (2012) 0.86
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clin Cancer Res (2015) 0.86
Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation. PLoS One (2014) 0.86
A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med (2015) 0.86
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov (2016) 0.86
Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep (2015) 0.85
Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov (2013) 0.85
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell (2016) 0.85
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer (2014) 0.84
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr) (2015) 0.84
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One (2015) 0.84
Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One (2013) 0.84
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. Oncotarget (2015) 0.83
Functional profiling of live melanoma samples using a novel automated platform. PLoS One (2012) 0.83
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance. Br J Pharmacol (2013) 0.83
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell (2004) 4.29
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25
Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett (2009) 3.19
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol Pharmacol (2009) 1.52
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res (2007) 5.01
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell (2006) 4.24
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev (2008) 3.67
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39